Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Oncol Lett ; 20(5): 221, 2020 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-32963627

RESUMO

The present study analyzed the role of transforming growth factor-ß1 (TGF-ß1) and tissue transglutaminase (TG2) in breast cancer, as well as their protein levels in MCF-7 cells treated with cisplatin. In addition, the present study investigated the effects of TG2 and TGF-ß1 in MCF-7 cells following TGF-ß1 and TG2 inhibition or TGF-ß1 induction. The protein levels of TG2 and TGF-ß1 in breast cancer tissues and in MCF-7 cells treated with cisplatin, TG2 and TGF-ß1 inhibitors or 10 ng/ml TGF-ß1 were analyzed by immunohistochemical staining, immunofluorescence and western blotting. The results revealed that the expression levels of TG2 and TGF-ß1 in breast cancer tissues were significantly higher compared with those in paracancerous tissues. The fluorescence intensity of TG2 and TGF-ß1 in MCF-7 cells treated with cisplatin was lower compared with that in untreated MCF-7 cells. Using bioinformatics analysis, the present study predicted that TGF-ß1 may be associated with TG2. In addition, the expression levels of TGF-ß1 and TG2 in MCF-7 cells treated with inhibitors of TGF-ß1 and TG2 were lower compared with those in untreated MCF-7 cells. By contrast, the expression levels of TGF-ß1 and TG2 in MCF-7 cells treated with TGF-ß1 were higher compared with those in untreated MCF-7 cells. Therefore, the present study demonstrated that TGF-ß1 and TG2 may serve an important role in breast cancer tissues and in MCF-7 cells. In addition, it was revealed that TG2 and TGF-ß1 may have a synergistic role in MCF-7 cells.

SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa